Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia
Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to...
Gespeichert in:
| Veröffentlicht in: | Leukemia & lymphoma 2002, Vol.43 (1), p.149-151 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 151 |
|---|---|
| container_issue | 1 |
| container_start_page | 149 |
| container_title | Leukemia & lymphoma |
| container_volume | 43 |
| creator | Perz, Jolanta Topaly, Julian Fruehauf, Stefan Hensel, Manfred Ho, Anthony D. |
| description | Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment. |
| doi_str_mv | 10.1080/10428190210178 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_informahealthcare_journals_10_1080_10428190210178</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19636887</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-d8cc6cba05835ab402bf5c282bfe1ed42904e6d68792c42fccddbbf0196837333</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxS1ERUvhyhH5xC3FdrKJc4Rt-SOt1Kpqz5bjjImLYwfboc134kPisCuhSu1pxnq_Nx7NQ-gdJWeUcPKRkopx2hJGCW34C3RCCWsLVpHy5dpXrMhqdYxex3hHCNm0NXuFjml28IaRE_RnB7_BYq_x9hwzUsDDFCBG4x2WrscXWhsl1bIC1ybND2aUHb4JINMILmHj8JVMJrcR35s04GuIJiaZJR_yw8opGvcDfy4UWIuvgrfLOA1eLckovIP5J4xG_vvqgGyH4N2qPcG9QUda2ghvD_UU3X65uNl-K3aXX79vP-0KVTGaip4rVatOkg0vN7KrCOv0RjGeC1DoK9aSCuq-5k3LskMr1fddpwlta142ZVmeog_7uVPwv2aISYwmrttJB36OIoNlzXmTwbM9qIKPMYAWU8gXCougRKz5iMf5ZMP7w-S5G6H_jx8CyUC7B4zTPozy3gfbiyQX64MO0ikTRfnscP7IO4C0aVAygLjzc3D5ZM_t9RegOLE0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19636887</pqid></control><display><type>article</type><title>Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Perz, Jolanta ; Topaly, Julian ; Fruehauf, Stefan ; Hensel, Manfred ; Ho, Anthony D.</creator><creatorcontrib>Perz, Jolanta ; Topaly, Julian ; Fruehauf, Stefan ; Hensel, Manfred ; Ho, Anthony D.</creatorcontrib><description>Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment.</description><identifier>ISSN: 1042-8194</identifier><identifier>EISSN: 1029-2403</identifier><identifier>DOI: 10.1080/10428190210178</identifier><identifier>PMID: 11908720</identifier><language>eng</language><publisher>United States: Informa UK Ltd</publisher><subject>Aged ; Anti Cd20 Antibody ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal - toxicity ; Antibodies, Monoclonal, Murine-Derived ; Antigens, CD20 - metabolism ; Antineoplastic Agents - standards ; Antineoplastic Agents - therapeutic use ; Antineoplastic Agents - toxicity ; B-cell Chronic Lymphocytic Leukemia (B-CLL) ; B-cell Prolymphocytic Leukemia (B-PLL) ; Biomarkers - analysis ; Cd20-expression ; Disease-Free Survival ; Drug Evaluation ; Flow Cytometry ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - mortality ; Leukemia, Prolymphocytic - diagnosis ; Leukemia, Prolymphocytic - drug therapy ; Leukemia, Prolymphocytic - mortality ; Male ; Middle Aged ; Monoclonal Antibody ; Rituximab ; Salvage Therapy ; Survival Rate ; Therapeutic Equivalency ; Treatment Outcome</subject><ispartof>Leukemia & lymphoma, 2002, Vol.43 (1), p.149-151</ispartof><rights>2002 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-d8cc6cba05835ab402bf5c282bfe1ed42904e6d68792c42fccddbbf0196837333</citedby><cites>FETCH-LOGICAL-c421t-d8cc6cba05835ab402bf5c282bfe1ed42904e6d68792c42fccddbbf0196837333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/10428190210178$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/10428190210178$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,4010,27900,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11908720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perz, Jolanta</creatorcontrib><creatorcontrib>Topaly, Julian</creatorcontrib><creatorcontrib>Fruehauf, Stefan</creatorcontrib><creatorcontrib>Hensel, Manfred</creatorcontrib><creatorcontrib>Ho, Anthony D.</creatorcontrib><title>Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia</title><title>Leukemia & lymphoma</title><addtitle>Leuk Lymphoma</addtitle><description>Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment.</description><subject>Aged</subject><subject>Anti Cd20 Antibody</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal - toxicity</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antigens, CD20 - metabolism</subject><subject>Antineoplastic Agents - standards</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Agents - toxicity</subject><subject>B-cell Chronic Lymphocytic Leukemia (B-CLL)</subject><subject>B-cell Prolymphocytic Leukemia (B-PLL)</subject><subject>Biomarkers - analysis</subject><subject>Cd20-expression</subject><subject>Disease-Free Survival</subject><subject>Drug Evaluation</subject><subject>Flow Cytometry</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</subject><subject>Leukemia, Prolymphocytic - diagnosis</subject><subject>Leukemia, Prolymphocytic - drug therapy</subject><subject>Leukemia, Prolymphocytic - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal Antibody</subject><subject>Rituximab</subject><subject>Salvage Therapy</subject><subject>Survival Rate</subject><subject>Therapeutic Equivalency</subject><subject>Treatment Outcome</subject><issn>1042-8194</issn><issn>1029-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9v1DAQxS1ERUvhyhH5xC3FdrKJc4Rt-SOt1Kpqz5bjjImLYwfboc134kPisCuhSu1pxnq_Nx7NQ-gdJWeUcPKRkopx2hJGCW34C3RCCWsLVpHy5dpXrMhqdYxex3hHCNm0NXuFjml28IaRE_RnB7_BYq_x9hwzUsDDFCBG4x2WrscXWhsl1bIC1ybND2aUHb4JINMILmHj8JVMJrcR35s04GuIJiaZJR_yw8opGvcDfy4UWIuvgrfLOA1eLckovIP5J4xG_vvqgGyH4N2qPcG9QUda2ghvD_UU3X65uNl-K3aXX79vP-0KVTGaip4rVatOkg0vN7KrCOv0RjGeC1DoK9aSCuq-5k3LskMr1fddpwlta142ZVmeog_7uVPwv2aISYwmrttJB36OIoNlzXmTwbM9qIKPMYAWU8gXCougRKz5iMf5ZMP7w-S5G6H_jx8CyUC7B4zTPozy3gfbiyQX64MO0ikTRfnscP7IO4C0aVAygLjzc3D5ZM_t9RegOLE0</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>Perz, Jolanta</creator><creator>Topaly, Julian</creator><creator>Fruehauf, Stefan</creator><creator>Hensel, Manfred</creator><creator>Ho, Anthony D.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>2002</creationdate><title>Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia</title><author>Perz, Jolanta ; Topaly, Julian ; Fruehauf, Stefan ; Hensel, Manfred ; Ho, Anthony D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-d8cc6cba05835ab402bf5c282bfe1ed42904e6d68792c42fccddbbf0196837333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Aged</topic><topic>Anti Cd20 Antibody</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal - toxicity</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antigens, CD20 - metabolism</topic><topic>Antineoplastic Agents - standards</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Agents - toxicity</topic><topic>B-cell Chronic Lymphocytic Leukemia (B-CLL)</topic><topic>B-cell Prolymphocytic Leukemia (B-PLL)</topic><topic>Biomarkers - analysis</topic><topic>Cd20-expression</topic><topic>Disease-Free Survival</topic><topic>Drug Evaluation</topic><topic>Flow Cytometry</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</topic><topic>Leukemia, Prolymphocytic - diagnosis</topic><topic>Leukemia, Prolymphocytic - drug therapy</topic><topic>Leukemia, Prolymphocytic - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal Antibody</topic><topic>Rituximab</topic><topic>Salvage Therapy</topic><topic>Survival Rate</topic><topic>Therapeutic Equivalency</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perz, Jolanta</creatorcontrib><creatorcontrib>Topaly, Julian</creatorcontrib><creatorcontrib>Fruehauf, Stefan</creatorcontrib><creatorcontrib>Hensel, Manfred</creatorcontrib><creatorcontrib>Ho, Anthony D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Leukemia & lymphoma</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perz, Jolanta</au><au>Topaly, Julian</au><au>Fruehauf, Stefan</au><au>Hensel, Manfred</au><au>Ho, Anthony D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia</atitle><jtitle>Leukemia & lymphoma</jtitle><addtitle>Leuk Lymphoma</addtitle><date>2002</date><risdate>2002</risdate><volume>43</volume><issue>1</issue><spage>149</spage><epage>151</epage><pages>149-151</pages><issn>1042-8194</issn><eissn>1029-2403</eissn><abstract>Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment.</abstract><cop>United States</cop><pub>Informa UK Ltd</pub><pmid>11908720</pmid><doi>10.1080/10428190210178</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1042-8194 |
| ispartof | Leukemia & lymphoma, 2002, Vol.43 (1), p.149-151 |
| issn | 1042-8194 1029-2403 |
| language | eng |
| recordid | cdi_informahealthcare_journals_10_1080_10428190210178 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Aged Anti Cd20 Antibody Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal - toxicity Antibodies, Monoclonal, Murine-Derived Antigens, CD20 - metabolism Antineoplastic Agents - standards Antineoplastic Agents - therapeutic use Antineoplastic Agents - toxicity B-cell Chronic Lymphocytic Leukemia (B-CLL) B-cell Prolymphocytic Leukemia (B-PLL) Biomarkers - analysis Cd20-expression Disease-Free Survival Drug Evaluation Flow Cytometry Humans Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Leukemia, Prolymphocytic - diagnosis Leukemia, Prolymphocytic - drug therapy Leukemia, Prolymphocytic - mortality Male Middle Aged Monoclonal Antibody Rituximab Salvage Therapy Survival Rate Therapeutic Equivalency Treatment Outcome |
| title | Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T15%3A07%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Level%20of%20CD%2020-expression%20and%20Efficacy%20of%20Rituximab%20Treatment%20in%20Patients%20with%20Resistant%20or%20Relapsing%20B-cell%20Prolymphocytic%20Leukemia%20and%20B-cell%20Chronic%20Lymphocytic%20Leukemia&rft.jtitle=Leukemia%20&%20lymphoma&rft.au=Perz,%20Jolanta&rft.date=2002&rft.volume=43&rft.issue=1&rft.spage=149&rft.epage=151&rft.pages=149-151&rft.issn=1042-8194&rft.eissn=1029-2403&rft_id=info:doi/10.1080/10428190210178&rft_dat=%3Cproquest_infor%3E19636887%3C/proquest_infor%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19636887&rft_id=info:pmid/11908720&rfr_iscdi=true |